Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials - Sorbonne Université
Journal Articles International Journal of Clinical Practice Year : 2021

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials

Francis Berenbaum
Centre de Recherche Saint-Antoine
Thomas Schnitzer
  • Function : Author
Alan Kivitz
  • Function : Author
Lars Viktrup
  • Function : Author
Elizabeth Johnston
  • Function : Author
Ruoyong Yang
  • Function : Author
Ed Whalen
  • Function : Author
Leslie Tive
  • Function : Author
David Semel
  • Function : Author

Domains

Life Sciences [q-bio]

francis berenbaum  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03994596

Submitted on : Friday, February 17, 2023-3:46:00 PM

Last modification on : Thursday, December 14, 2023-1:50:38 PM

Consult the full text

Dates and versions

hal-03994596 , version 1 (17-02-2023)

Identifiers

Cite

Francis Berenbaum, Thomas Schnitzer, Alan Kivitz, Lars Viktrup, Elizabeth Johnston, et al.. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials. International Journal of Clinical Practice, 2021, 75 (12), ⟨10.1111/ijcp.14975⟩. ⟨hal-03994596⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

U938 SORBONNE-UNIVERSITE SU-MEDECINE
3 View
0 Download

Altmetric

Share

More